Tivicay - opinion on variation to marketing authorisation
Opinion
EMA has issued an opinion on a change to this medicine's authorisation
dolutegravir
Post-authorisationHuman
Opinion
On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tivicay. The marketing authorisation holder for this medicinal product is ViiV Healthcare B.V.
The CHMP adopted an extension to an existing indication for Tivicay dispersable tablets, as follows:
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents,and children and term neonates from birthof at least 4 weeks of age or older and weighing at least 2 3 kg.
For information, the indication for Tivicay film-coated tablets remain unchanged, as follows:
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
New text in bold, removed text as strikethrough
CHMP post-authorisation summary of positive opinion for Tivicay (VR-0000351003)